Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Alone among the best-known social platforms, Snapchat has failed to generate much enthusiasm from pharma. Here's why — and here's why that may change.
Read the August 2017 issue in its entirety, including our recap of the MM&M Hall of Femme event.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Patients are demanding more of their healthcare experience — and that includes from their healthcare providers, according to two new surveys.
Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to change.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
Participants in this roundtable explore how digital forms of data are poised to illuminate the reimbursement pathway, as market access gets its closeup.
Susan Sweeney has earned a reputation for such pragmatism and attentiveness to the things that really matter.
Read the 2017 Agency Issue in its entirety.
Meet 13 of our 16 Hall of Femme honorees.
Frustrated by its inability to empathize with patients, pharma has turned to tech to teach providers and caregivers what illness really feels like.
McCann Health, Cannes Lions Healthcare Network of the Year, hosted a roundtable to discuss the role of creativity in a new world order where populism is undermining trust.
Here are nine agencies that are gaining traction in healthcare marketing.
Discover how M&A activity in 2016 and 2017 has reshaped North American healthcare agencies and the holding companies that own them.
Here you'll find the last four years of the MM&M Agency Issue.
Healthcare networks instigated a broad set of changes in a grand embrace of non-pharma business that diversified revenue streams and took specialist agencies out of their comfort zones.
Havas Health & You, WPP Health & Wellness, and Klick Health reported the highest revenue last year.
The CEOs of the industry's largest holding companies discuss how they're reasserting their businesses.
Read on for more about the top performing firms, the trends shaping the business, and the story behind each of the top 100 agencies.
Here you'll find everything from the Patient Journey 2017 supplement to our June issue.
Here you'll find everything from our June 2017 issue, including our Pharma Report, our Hall of Femme, and two roundtable discussions on media and oncology.
In apportioning their media budgets, pharma companies continue to straddle the line between new and traditional strategies.
Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family support.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Five sector pros discuss adapting to patient-centricity and how pinpointing patient needs leads to success.
Here you'll find everything from our May 2017 issue, including our Top 40 Transformers, deep dive into autoimmune drugs, and more.
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
Here you'll find Sara Holoubek's deep dive into how pharma is tackling some of its biggest challenges.
Under Duato, the leadership team for Johnson & Johnson's pharma group includes six women. "We don't just talk about it," he says.
Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.
Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.
While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.
AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.
Here you'll find everything you need to know from MM&M's April 2017 issue, including our DTC report, our deep dive into respiratory drugs, and more.
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.
A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.
A WebMD survey finds that patients are more engaged when they share their own health with their doctors.
We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.
Drugmakers again spent more on DTC advertising in 2016 than the year before.
Pharma spent more than $4 billion on TV ads last year. Empowered patient communities weren't impressed. Has DTC on TV reached its moment of reckoning?
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.
Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.
Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, and more.
Seven execs from A-list agencies weigh in on talent acquisition and retention.
While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
Here you'll find everything you need to know from MM&M's February 2017 issue, including our payer state of the union, social media spotlight, and more.
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.
He describes his current charge as "transforming a more creative occupation into a science."
Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.
This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
Here you'll find everything you need to know from MM&M's January 2017 issue, including our health-tech preview, a deep dive into data science, and report on digital innovation from Japanese drugmakers.
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.
Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."
Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.
The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.
One pharmacy director would like to see a lot more comparative data about new therapies.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.
The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.
Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.
Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.
That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"
Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.
"In Australia, we are the healthcare industry," he says.
Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.
When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.
The first step is to seek leadership support, she says.
The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.
Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.
Here you'll find everything you need to know from MM&M's December 2016 issue, including our policy outlook for pharma in a Republican-led White House and Congress and the exclusive pipeline report.
Here's a look at 100 experimental therapies in late-stage clinical trials.
More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.
Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.
If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.
How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information
Read the November 2016 issue in its entirety, including our inaugural Health Influencer 50 selections.
With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?
As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare.
Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.